Cryopreservation of isolated primary rat hepatocytes: enhanced survival and long-term hepatospecific function
- PMID: 15622000
- PMCID: PMC1356855
- DOI: 10.1097/01.sla.0000149303.48692.0f
Cryopreservation of isolated primary rat hepatocytes: enhanced survival and long-term hepatospecific function
Abstract
Objective: To investigate the long-term effect of cryopreservation on hepatocyte function, as well as attempt to improve cell viability and function through the utilization of the hypothermic preservation solution, HypoThermosol (HTS), as the carrier solution.
Summary background data: Advances in the field of bioartificial liver support have led to an increasing demand for successful, efficient means of cryopreservation of hepatocytes.
Methods: Fresh rat hepatocytes were cryopreserved in suspension in culture media (Media-cryo group) or HTS (HTS-cryo group), both supplemented with 10% DMSO. Following storage up to 2 months in liquid nitrogen, cells were thawed and maintained in a double collagen gel culture for 14 days. Hepatocyte yield and viability were assessed up to 14 days postthaw. Serial measurements of albumin secretion, urea synthesis, deethylation of ethoxyresorufin (CYT P450 activity), and responsiveness to stimulation with interleukin-6 (IL-6) were performed.
Results: Immediate postthaw viability was 60% in Media-cryo and 79% in HTS-cryo, in comparison with control (90%). Albumin secretion, urea synthesis and CYT P450 activity yielded 33%, 55%, and 59% in Media-cryo and 71%, 80%, and 88% in HTS-cryo, respectively, compared with control (100%). Assessment of cellular response to IL-6 following cryopreservation revealed a similar pattern of up-regulation in fibrinogen production and suppression of albumin secretion compared with nonfrozen controls.
Conclusions: This study demonstrates that isolated rat hepatocytes cryopreserved using HTS showed high viability, long-term hepatospecific function, and response to cytokine challenge. These results may represent an important step forward to the utilization of cryopreserved isolated hepatocytes in bioartificial liver devices.
Figures





References
-
- Khalili TM, Navarro A, Ting P, et al. Bioartificial liver treatment prolongs survival and lowers intracranial pressure in pigs with fulminant hepatic failure. Artif Organs. 2001;25:566–570. - PubMed
-
- Sosef MN, Abrahamse LS, van De Kerkhove MP, et al. Assessment of the AMC-bioartificial liver in the anhepatic pig. Transplantation. 2002;73:204–209. - PubMed
-
- Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology. 1996;24:1446–1451. - PubMed
-
- van de Kerkhove MP, Di Florio E, Scuderi V, et al. Phase I clinical trial with the AMC-bioartificial liver. Int J Artif Organs. 2002;25:950–959. - PubMed
-
- Stevens A, Busuttil RW, Hari S, et al. An interim analysis of a phase II/III prospective, randomized, multicenter, controlled trial of the HepatAssist bioartificial support system for the treatment of fulminant hepatic failure. Hepatology. 2001;34:299A.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources